Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T19:48:34.975Z.
Calculation as of: 2026-10-06T19:48:34.975Z.
Quote observation: 2026-10-06T19:44:03.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f827d960650d67e3900ac6098f04a5e2078fd3b8121965df68c70cd2fd602cdf
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
Anbio Biotechnology Class A Ordinary Shares
Market Cap
$208.48M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$210.17M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$210.80M
Operating Cash Flow Yield
N/A
TTM Avg
25.60%
3Y Avg
25.60%
5Y Avg
25.60%
Market Cap
$212.22M
Operating Cash Flow Yield
2.80%
TTM Avg
2.54%
3Y Avg
2.69%
5Y Avg
2.62%
Market Cap
$207.70M
Operating Cash Flow Yield
3.49%
TTM Avg
3.82%
3Y Avg
6.32%
5Y Avg
5.85%
Market Cap
$213.63M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$215.21M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$206.40M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Anbio Biotechnology Class A Ordinary Shares (NNNN) | $208.48M | N/A | N/A | N/A | N/A |
| Compugen Ltd. (CGEN)vs › | $210.85M | N/A | N/A | N/A | N/A |
| Sionna Therapeutics, Inc. (SION)vs › | $210.17M | N/A | N/A | N/A | N/A |
| Entrada Therapeutics, Inc. (TRDA)vs › | $210.80M | N/A | 25.60% | 25.60% | 25.60% |
| Niagen Bioscience Inc (NAGE)vs › | $212.22M | 2.80% | 2.54% | 2.69% | 2.62% |
| Pro-Dex, Inc. (PDEX)vs › | $207.70M | 3.49% | 3.82% | 6.32% | 5.85% |
| Lyell Immunopharma, Inc. (LYEL)vs › | $213.63M | N/A | N/A | N/A | N/A |
| Prelude Therapeutics Incorporated (PRLD)vs › | $215.21M | N/A | N/A | N/A | N/A |
| Electra Therapeutics Inc. (ETRA)vs › | $206.40M | N/A | N/A | N/A | N/A |
| Whitehawk Therapeutics Inc (WHWK)vs › | $205.23M | N/A | 0.34% | 0.34% | 0.34% |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
